Table 2.
Multivariable logistic regression analysis of multiple serum composite indicators and obstructive sleep apnea.
| Variables | Model I OR (95% CI) | P-value | Model II OR (95% CI) | P-value | Model III OR (95% CI) | P-value |
|---|---|---|---|---|---|---|
| MHR | ||||||
| Q1 0.08–0.20 |
Ref | Ref | Ref | |||
| Q2 0.20–0.26 |
2.92 (1.46, 5.87) | 0.003 | 2.61 (1.18, 5.79) | 0.018 | 1.80 (0.76, 4.31) | 0.184 |
| Q3 0.26–0.35 |
4.75 (2.35, 9.59) | <0.001 | 3.90 (1.72, 8.85) | 0.001 | 3.10 (1.23, 7.79) | 0.016 |
| Q4 0.35–1.22 |
6.73 (3.28, 13.80) | <0.001 | 4.40 (1.87, 10.32) | <0.001 | 2.26 (0.85, 6.01) | 0.101 |
| PHR | ||||||
| Q1 40.98–126.49 |
Ref | Ref | Ref | |||
| Q2 126.49–174.01 |
2.11 (1.05, 4.26) | 0.037 | 1.45 (0.66, 3.19) | 0.349 | 1.08 (0.45, 2.58) | 0.861 |
| Q3 174.01–222.12 |
4.49 (2.23, 9.06) | <0.001 | 2.47 (1.09, 5.62) | 0.031 | 1.59 (0.63, 4.00) | 0.327 |
| Q4 222.12-476.71 |
10.80(5.07,23.03) | <0.001 | 5.62(2.38,13.32) | <0.001 | 3.20 (1.21, 8.49) | 0.019 |
| NHHR | ||||||
| Q1 0.54–2.20 |
Ref | Ref | Ref | |||
| Q2 2.20–2.91 |
2.82 (1.43, 5.59) | 0.003 | 2.01 (0.92, 4.35) | 0.078 | 1.59 (0.67, 3.73) | 0.290 |
| Q3 2.91–3.63 |
3.70 (1.86, 7.34) | <0.001 | 2.74 (1.24, 6.02) | 0.013 | 1.64 (1.68, 3.95) | 0.267 |
| Q4 3.63–9.87 |
5.18 (2.58, 10.42) | <0.001 | 3.41 (1.52, 7.64) | 0.003 | 2.00 (0.81, 4.93) | 0.135 |
| AIP | ||||||
| Q1 (−0.68)–(−0.13) |
Ref | Ref | Ref | |||
| Q2 (−0.13)–0.08 |
2.92 (1.46, 5.87) | 0.003 | 3.33 (1.50, 7.39) | 0.003 | 2.43 (1.02, 5.74) | 0.044 |
| Q3 0.08–0.29 |
5.02 (2.48, 10.16) | <0.001 | 4.85 (2.16, 10.87) | <0.001 | 2.49 (1.00, 6.21) | 0.050 |
| Q4 0.29–1.28 |
6.33 (2.10, 12.95) | <0.001 | 5.35 (2.32, 12.31) | <0.001 | 2.90 (1.12, 7.53) | 0.028 |
| UHR | ||||||
| Q1 0.00–0.19 |
Ref | Ref | Ref | |||
| Q2 0.19–0.28 |
2.38 (1.14, 4.97) | 0.020 | 2.54 (1.11, 5.82) | 0.027 | 1.60 (0.66, 3.87) | 0.301 |
| Q3 0.28–0.38 |
6.71 (3.22, 13.99) | <0.001 | 5.59 (2.35, 13.32) | <0.001 | 2.94 (1.13, 7.65) | 0.027 |
| Q4 0.38–0.90 |
16.00 (7.19, 35.61) | <0.001 | 10.0 8(3.98, 25.55) | <0.001 | 4.33 (1.52, 12.37) | 0.006 |
| RC/HDL | ||||||
| Q1 (−1.00)–0.34 |
Ref | Ref | Ref | |||
| Q2 0.34–0.48 |
3.19 (1.60, 6.37) | <0.001 | 3.27 (1.47, 7.26) | 0.004 | 2.82 (1.18, 6.75) | 0.020 |
| Q3 0.48–0.68 |
5.24 (2.60, 10.57) | <0.001 | 5.07 (2.23, 11.54) | <0.001 | 3.36 (1.38, 8.16) | 0.007 |
| Q4 0.68–5.51 |
4.18 (2.09, 8.38) | <0.001 | 3.83 (1.68, 8.74) | 0.001 | 2.52 (1.03, 6.14) | 0.042 |
| SIRI | ||||||
| Q1 0.15–0.49 |
Ref | Ref | Ref | |||
| Q2 0.49–0.72 |
0.71 (0.37, 1.35) | 0.292 | 0.56 (0.26, 1.19) | 0.130 | 0.65 (0.28, 1.54) | 0.329 |
| Q3 0.72–1.07 |
1.28 (0.67, 2.43) | 0.458 | 1.10 (0.52, 2.35) | 0.806 | 1.06 (0.46, 2.47) | 0.886 |
| Q4 1.07–7.71 |
1.24 (0.65, 2.35) | 0.513 | 1.11 (0.52, 2.35) | 0.786 | 1.11 (0.47, 2.60) | 0.809 |
Model I: unadjusted model. Model II: adjusted for age, gender, drinking status, smoking status. Model III: adjusted for variables in Model II plus BMI, hypertension, diabetes status. BMI, body mass index; MHR, Monocyte to HDL Ratio; PHR, Platelet to HDL Ratio; NHHR, Non-HDL to HDL Ratio; AIP, Atherogenic Index of Plasma; UHR, Uric acid to HDL Ratio; RC/HDL, Remnant Cholesterol to HDL Ratio; SIRI, Systemic Inflammation Response Index; OR, odds ratio; 95% CI, 95% confidence interval.